NCT02014259View on ClinicalTrials.gov

Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function

PHASE1CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

December 11, 2013

Primary Completion Date

October 24, 2014

Study Completion Date

October 24, 2014

Conditions
DiabetesDiabetes Mellitus, Type 2Healthy
Interventions
DRUG

semaglutide

Once daily oral administration of semaglutide formulated with SNAC. Dose escalation, with 5 days on 5 mg followed by 5 days on 10 mg

Trial Locations (4)

1076

Novo Nordisk Investigational Site, Budapest

1115

Novo Nordisk Investigational Site, Budapest

17000

Novo Nordisk Investigational Site, Prague

50005

Novo Nordisk Investigational Site, Hradec Králové

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY